Bristol-Myers Squibb has awarded grants totaling $175,000 to the American Cancer Society Eastern Division and Princeton HealthCare System (PHCS) to support comprehensive navigation services for patients with cancer both independently and as part of a collaborative effort among several hospitals in central New Jersey.
Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.
NEW YORK (AP) - Drug maker Bristol-Myers Squibb Co. said Thursday the European Commission has approved its treatment Yervoy for use in adults with previously treated advanced melanoma, the deadliest type of skin cancer.
The New York drug maker said it will work to expedite Yervoy's availability across the European Union.
U.S. regulators approved Yervoy in March for advanced melanoma in both newly diagnosed patients and those who have failed on another therapy. The drug works by stimulating the immune system to recognize and then destroy cancer cells.